Vivos Therapeutics Shares Outstanding History (VVOS)
Vivos Therapeutics reported 9.3M shares outstanding at the end of fiscal 2025.
View full Vivos Therapeutics company overviewVivos Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 9.3M | 3.4M | +57.68% |
| 2024 | 2024-12-31 | 5.9M | 4.1M | +221.15% |
| 2023 | 2023-12-31 | 1.8M | 913,285 | +99.21% |
| 2022 | 2022-12-31 | 920,592 | −22.1M | −96.00% |
| 2021 | 2021-12-31 | 23.0M | 4.8M | +26.37% |
| 2020 | 2020-12-31 | 18.2M | 5.8M | +46.33% |
| 2019 | 2019-12-31 | 12.4M | — | — |
Vivos Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 14.5M | 7.2M | +98.39% |
| Q1 2026 | 2026-03-31 | 13.5M | 7.6M | +128.98% |
| Q4 2025 | 2025-12-31 | 9.3M | 3.4M | +57.68% |
| Q3 2025 | 2025-09-30 | 8.3M | 3.5M | +73.48% |
| Q2 2025 | 2025-06-30 | 7.3M | 3.9M | +115.34% |
| Q1 2025 | 2025-03-31 | 5.9M | 3.2M | +115.63% |
| Q4 2024 | 2024-12-31 | 5.9M | 4.1M | +221.15% |
| Q3 2024 | 2024-09-30 | 4.8M | 3.6M | +298.02% |
| Q2 2024 | 2024-06-30 | 3.4M | −26.5M | −88.63% |
| Q1 2024 | 2024-03-31 | 2.7M | −27.2M | −90.87% |
| Q4 2023 | 2023-12-31 | 1.8M | −21.2M | −92.03% |
| Q3 2023 | 2023-09-30 | 1.2M | −21.8M | −94.80% |
| Q2 2023 | 2023-06-30 | 29.9M | 6.9M | +30.06% |
| Q1 2023 | 2023-03-31 | 29.9M | 6.9M | +30.06% |
| Q4 2022 | 2022-12-31 | 23.0M | 0 | 0.00% |
| Q3 2022 | 2022-09-30 | 23.0M | 0 | 0.00% |
| Q2 2022 | 2022-06-30 | 23.0M | 200,000 | +0.88% |
| Q1 2022 | 2022-03-31 | 23.0M | 4.8M | +26.36% |
| Q4 2021 | 2021-12-31 | 23.0M | 4.8M | +26.37% |
| Q3 2021 | 2021-09-30 | 23.0M | 10.6M | +84.92% |
| Q2 2021 | 2021-06-30 | 22.8M | — | — |
| Q1 2021 | 2021-03-31 | 18.2M | — | — |
| Q4 2020 | 2020-12-31 | 18.2M | — | — |
| Q4 2019 | 2019-12-31 | 12.4M | — | — |
Vivos Therapeutics shares outstanding trends
Over the last five reported fiscal years, Vivos Therapeutics's shares outstanding moved from 18.2M to 9.3M, a change of −8.9M. The latest reported quarter, Q2 2026, shows 14.5M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics filings at SEC.gov ↗